SpliceBio takes over Times Square! 🗽 Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower. Huge thanks to our team & investors powering the next wave of genetic medicines! 💡

Our Clinical Project Manager Lauren Hauser (pictured in pink) recently represented SpliceBio at an event hosted by the @CarrollCenter.  We value opportunities to connect with organizations like the Carroll Center that share our commitment to supporting the vision loss community.

This #WorldSightDay, we’re raising awareness of Stargardt disease and the impact progressive central vision loss can have on everyday activities like reading a book. At SpliceBio, we’re advancing SB-007, our investigational gene therapy for #Stargardt disease.

Join our CBO Gerard Caelles at #Sachs_BEF in Basel this week. He will present our work in #CNS and join the Neuroscience Innovation Panel with other industry leaders.

Our CEO Miquel Vila-Perello is heading to Phoenix for @alliancerm 2026 Cell & Gene Meeting on the Mesa. We look forward to connecting with colleagues across the cell and gene therapy community on Monday and throughout the week. We’ll meet you at #CGMesa26!

We’re honored to be nominated for the 2026 Prix Galien Patient First Award in Honor of Michael J. Fox. This recognition reflects our work alongside the #StargardtDisease community to deepen our understanding of the disease and advance new treatment options. Thank you @GalienFdn.

At #ISER2026, our Head of Ophthalmology, Julián Esteve will present on how our protein splicing platform is overcoming AAV cargo limits to unlock delivery of large genes. He'll also share how the technology is being applied in SB-007, our lead program for #Stargardt disease.

Today is Rare Chromosome and Gene Disorder Awareness Day - a time to recognize the individuals and families affected by rare genetic conditions, including inherited retinal diseases such as #Stargardt disease. We honor their resilience and the importance of continued innovation.

This Monday, we're in Leicester for @UKEyeGenetics Group (UK-EGG) 2026! Our CMO will present on conducting clinical trials, navigating the regulatory process and the importance of communication - fundamental elements to our mission of advancing #geneticmedicines.

Last week, our team came together for a retreat filled with reflection, connection, and plenty of laughs! Experiences like these reinforce something we believe deeply: investing in our people is essential to building a strong culture and advancing our mission.

#Stargardt disease is caused by mutations in ABCA4 - a gene too large for traditional gene therapy. We're advancing protein splicing to enable large-gene delivery and address the root cause of a disease with no approved treatments.

Great time at #ARVO2026 & #ASGCT2026! We were proud to share progress on our clinical program SB-007 for #Stargardt disease and engage in conversations with the broader #genetherapy community. Thank you to everyone who connected. We’re energized by the momentum!

#Stargardt disease has no approved treatments. This #HealthyVisionMonth, we’re raising awareness of inherited retinal diseases. At SpliceBio, we’re working to advance genetic medicines using protein splicing to address diseases caused by mutations in large genes.

We’re heading to #ASGCT2026 next week! Looking forward to connecting with the community, sharing insights, and contributing to the conversation around #genetherapy at the @ASGCTherapy Annual Meeting. See you there!

Great science starts with great people. Today, we celebrate the SpliceBio team whose passion and collaboration power our work in genetic medicines. Thank you for all you do. Happy #InternationalWorkersDay!